Abstract:Aim: Cancer as a complex disease poses significant challenges for both diagnosis and treatment. Researchers have been exploring various avenues to find effective therapeutic strategies, with a particular emphasis on cellular signaling pathways and immunotherapy. One such pathway that has recently been suggested is the PD-1/PD-L1 pathway, which is an immune checkpoint signaling system that plays an important role in regulating the immune system and maintaining tissue homeostasis. Cancer cells exploit this pathway by producing PD-L1, which attaches to PD-1 on T cells, thus inhibiting immune responses and enabling the cancer cells to escape detection by the immune system. This study aimed to evaluate the role of the PD-1/PD-L1 pathway in cancer pathogenesis and treatment. Method: This study was performed based on the principles of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). All in vitro , in vivo , and clinical studies that were published in English have been considered during a thorough search of the Scopus, Web of Science, and PubMed databases without date restriction until March 2024. Results: According to the studies reviewed, the PD-1/PD-L1 signaling axis suggests promising therapeutic effects on various types of cancers such as non-small cell lung cancer, melanoma, breast cancer, hepatocellular carcinoma, squamous cell carcinoma, and colorectal cancer, among others. Additionally, research suggests that immune checkpoint inhibitors that block PD1/PD-L1, such as pembrolizumab, atezolizumab, nivolumab, durvalumab, cemiplimab, avelumab, etc. , can effectively prevent tumor cells from escaping the immune system. Moreover, there might be a possible interaction between microbiome, obesity, etc. on immune mechanisms and on the immune checkpoint inhibitors (ICIs). Conclusion: Although we have gained considerable knowledge about ICIs, we are still facing challenges in effectively prescribing the appropriate ICIs for individual patients. This is largely due to the complex interactions between different intracellular pathways, which need to be thoroughly studied. To resolve this issue, it is necessary to conduct more reliable clinical trials that can produce a scientific consensus.

Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events

Tumor Immune Checkpoints and Their Associated Inhibitors

A comprehensive review of immune checkpoint inhibitors for cancer treatment

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons

Immune Checkpoint Inhibitors' challenges, mechanisms and management

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?

Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Therapeutic importance, general and endocrine adverse effects of immune checkpoint inhibitors I: mechanism of action and therapeutic use

Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review

PD-1/PD-L1 Blockade in Cancer Immunotherapy: Clinical Benefits, Limitations and Beyond

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

Toxicity in the era of immune checkpoint inhibitor therapy

The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review

The Current Achievements and Existing Shortage of Immune Checkpoint Inhibitor

Increasing cure rates of solid tumors by immune checkpoint inhibitors

Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer

From tumor to tolerance: A comprehensive review of immune checkpoint inhibitors and immune-related adverse events